Clinical Trial

KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Primary and Secondary Progressive Multiple Sclerosis
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-04-23; most recent amendment 2025-01-10.
Status change: Recruiting → Active, Not Recruiting 2025-01-10
Status change: Not Yet Recruiting → Recruiting 2024-09-27
Trial Details
NCT Number NCT06384976
Lead Sponsor Kyverna Therapeutics
Conditions Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, MS
Enrollment 120 participants
Start Date 2024-09-20
Primary Completion 2027-04 (estimated)
Study Completion 2029-01 (estimated)
Updated on ClinicalTrials.gov 2025-01-13